Common mutation in gliomas could make them less resistant to treatment

Common mutation in gliomas could make them less resistant to treatment

Posted 14 October, 2021 at 13:59

Author Jessica McClory on behalf of In Sues Name


Researchers have found that a common mutation in gliomas sensitises them to immunotherapy and that this could have broader therapeutic implications for all glioma patients.

The mutation of a single amino acid from arginine to histidine in a subset of these brain tumours sensitises them to treatment with immune-stimulating therapy, to which they would otherwise be largely resistant.

Having discovered this sensitivity and mapped the underlying mechanisms, the research team identified a blood growth factor secreted by tumours harbouring the mutation that holds promise for making treatments against gliomas more effective.

In a mouse model of glioma without the IDH1 mutation, administering G-CSF, the blood growth factor produced by their mutant cousins, more than doubled median survival times. When immunotherapy was also added in, the effect was even more profound, the study found.

Original source: Common Mutation in Gliomas Sensitizes Them to Immunotherapy (genengnews.com)

More from In Sues Name

Epigenetics & the future of Glioblastoma treatment
Latest News

Epigenetics & the future of Glioblastoma treatment

22 October 2021
Jailbreak - TODAY!
Social Media Post

Jailbreak - TODAY!

21 October 2021
Revolutionary brain cancer treatment on the horizon
Latest News

Revolutionary brain cancer treatment on the horizon

19 October 2021
JAILBREAK - This Thursday
Social Media Post

JAILBREAK - This Thursday

18 October 2021
Card image cap
user

In Sues Name

Charity

Profile Feed
In Sue’s Name was founded in 2014 by David Taylor in memory of his beloved daughter Sue Blasotta, who died in 2011 of brain tumours. Sue was devoted to her husband Joe and their children Sasha and Daniel. She adored her career, first in recruitment with Reed Employment and then caring for ch...

19

Press Releases